| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
| ln Vitro |
2-Fluoroadenine (2 μM; 4 hours) targets one or more enzymes involved in the creation of RNA or proteins, which slows the development of CEM cells [1]. 2- Non-proliferating MRC-5 cells demonstrate cytotoxicity in response to fluorroadenine (0-1000 μM; 96 hours) [1]. 2- Protein, RNA, and DNA synthesis is inhibited in Balb-3T3 cells cultured in serum-free media by fluoroadenine (0.22, 2.2, and 22 μM; 30 hours) [1].
|
|---|---|
| Cell Assay |
Cell Proliferation Assay
Cell Types: CEM cells [1] Tested Concentrations: 2 μM Incubation Duration: 4 hrs (hours) Experimental Results: Inhibition of CEM cell growth by targeting one or more enzymes involved in RNA or protein synthesis. cell cytotoxicity assay Cell Types: MRC-5 cells [1] Tested Concentrations: 0-1000 μM Incubation Duration: 4 hrs (hours) Experimental Results: Cytotoxicity was demonstrated in non-proliferating MRC-5 cells. |
| References | |
| Additional Infomation |
2-fluoroadenine is an organofluorine compound that is adenine in which the hydrogen at position 2 (the carbon between the two nitrogens of the pyrimidine ring) is replaced by a fluorine. It has a role as an antineoplastic agent. It is an organofluorine compound and a member of purines.
2-Fluoroadenine is a fluorinated heterocyclic 2-ring compound. 2-fluoroadenine is the base moiety for many carbocyclic and acyclic nucleoside analogues, which may be used in antineoplastic studies. |
| Molecular Formula |
C5H4FN5
|
|---|---|
| Molecular Weight |
163.12
|
| Exact Mass |
153.045
|
| CAS # |
700-49-2
|
| PubChem CID |
12790
|
| Appearance |
White to off-white solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
676.9±58.0 °C at 760 mmHg
|
| Melting Point |
>350 °C(lit.)
|
| Flash Point |
363.2±32.3 °C
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
| Index of Refraction |
1.783
|
| LogP |
-0.01
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
11
|
| Complexity |
154
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
WKMPTBDYDNUJLF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H4FN5/c6-5-10-3(7)2-4(11-5)9-1-8-2/h1H,(H3,7,8,9,10,11)
|
| Chemical Name |
1H-Purin-6-amine, 2-fluoro-
|
| Synonyms |
2-Fluoroadenine NSC-27364 NSC27364NSC 27364
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~20.83 mg/mL (~136.04 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (13.58 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (13.58 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.1305 mL | 30.6523 mL | 61.3046 mL | |
| 5 mM | 1.2261 mL | 6.1305 mL | 12.2609 mL | |
| 10 mM | 0.6130 mL | 3.0652 mL | 6.1305 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00625430 | UNKNOWN STATUS | Biological: Gene Directed Enzyme Prodrug Therapy, FP253/Fludarabine |
Prostate Cancer | Biotech Equity Partners Pty Ltd | 2008-03 | Phase 1 |
| NCT01310179 | COMPLETEDWITH RESULTS | Genetic: Ad/PNP and fludarabine monophosphate | Head and Neck Cancer | PNP Therapeutics, Inc. | 2011-02 | Phase 1 |
| NCT03935347 | WITHDRAWN | Drug: Cyclophosphamide Drug: Fludarabine Drug: Fludarabine Phosphate |
Metastatic Bladder Urothelial Carcinoma Metastatic Renal Pelvis Urothelial Carcinoma Metastatic Ureter Urothelial Carcinoma Metastatic Urethral Urothelial Carcinoma |
Roswell Park Cancer Institute | 2019-06-20 | Phase 2 |
| NCT03326921 | SUSPENDED | Biological: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR Drug: Fludarabine Other: Laboratory Biomarker Analysis |
Acute Biphenotypic Leukemia Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Acute Undifferentiated Leukemia |
Fred Hutchinson Cancer Center | 2018-02-23 | Phase 1 |
| NCT04007029 | RECRUITING | Biological: Chimeric Antigen Receptor T-Cell Therapy Drug: Cyclophosphamide Drug: Fludarabine Phosphate Biological: Tocilizumab |
CD19 Positive CD20 Positive Recurrent Chronic Lymphocytic Leukemia Recurrent Diffuse Large B-Cell Lymphoma |
Jonsson Comprehensive Cancer Center | 2019-10-04 | Phase 1 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
